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The influence of intercalating perfluorohexane
into lipid shells on nano and microbubble
stability†
Radwa H. Abou-Saleh,ab Sally A. Peyman,a Benjamin R. G. Johnson,a
Gemma Marston,c Nicola Ingram,c Richard Bushby,d P. Louise Coletta,c
Alexander F. Markhamc and Stephen D. Evans*a
Microbubbles are potential diagnostic and therapeutic agents. In vivo stability is important as the bubbles
are required to survive multiple passages through the heart and lungs to allow targeting and delivery.
Here we have systematically varied key parameters affecting microbubble lifetime to significantly
increase in vivo stability. Whilst shell and core composition are found to have an important role in
improving microbubble stability, we show that inclusion of small quantities of C6F14 in the microbubble
bolus significantly improves microbubble lifetime. Our results indicate that C6F14 inserts into the lipid
shell, decreasing surface tension to 19 mN m1, and increasing shell resistance, in addition to saturating
the surrounding medium. Surface area isotherms suggest that C6F14 incorporates into the acyl chain
region of the lipid at a high molar ratio, indicating B2 perfluorocarbon molecules per 5 lipid molecules.
The resulting microbubble boluses exhibit a higher in vivo image intensity compared to commercial
compositions, as well as longer lifetimes.
1 Introduction
Microbubbles (MBs) used for contrast enhanced ultrasound
(CEUS) imaging are micron sized gas encapsulated spheres,
stabilized with a shell made of biocompatible materials such as
proteins, surfactants, phospholipids or polymers. These MBs
are capable of circulating in the vasculature and their high
acoustic impedance mismatch with the surrounding tissue
leads to strong ultrasound scattering resulting in enhanced
contrast in US imaging. Recently there has been considerable
interest in the development of MBs as vehicles for drug
delivery1,2 by loading them with drug-filled liposomes, attaching
genes to the shell,3–5 or filling the core with a therapeutic gas.6,7
The MB complex can be targeted to the required location using
antibodies, or other ligands, to provide a route for targeted,
triggered delivery.8 Furthermore, it has been demonstrated
that bursting the MBs using an ultrasound pulse gives rise to
sonoporation of cells in the immediate vicinity of the MBs,
leading to an enhanced therapeutic uptake.9,10 Their changing
role requires that MBs be re-engineered to improve their func-
tional performance, with the key MB parameters being size and
dispersity, biocompatibility, shell stiffness and MB lifetime.5,11
For clinical and preclinical applications MBs are typically
desired to be between 1–8 mm in diameter. Control over size can
be achieved by selecting a suitable production technique.
Sonication and mechanical agitation are the common methods
for MB production.12,13 They produce broad poly-disperse size
distributions with a polydispersity index of B150%, with the
majority of MBs being in the range of o8 mm,14 and are
currently used for diagnostic imaging.15,16 Coaxial electro-
hydrodynamic atomisation14,17 produces bubbles which can
be of a controllable size between 1 and 25 mm and with a
moderate dispersity index of B30%. For the highest quality
monodisperse MB production, the best control over the size
and the dispersity index has come about through the use of
flow-focus microfluidic (MF) technology.18–21 However, in this
approach the MB concentration tends to be low (B106 MB mL1)
compared to the 108 MB mL1 used in a single bolus for in vivo
imaging experiments. Recently Peyman et al. introduced a rapid
pressure-drop on a chip technique, which led to the production
of nano and micron sized bubbles that were typically less than
2 mm in diameter, at high concentrations (41010 and 108 MBmL1
respectively).22 Post production MBs are prone to fusion and
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dissolution unless they are stabilized with a suitable coating.
Furthermore, such MBs should not only be stable in vitro but
also in vivo, where they are required to survive multiple pas-
sages through the heart and lungs for successful diagnostic
imaging, and possibly longer for therapeutic applications
requiring the effective targeting and release of drug payloads.
Control over the in vitro and in vivo stability (or lifetime) of
MBs depends upon three main considerations; (i) the condi-
tions of the surrounding medium, such as the temperature,
pressure and concentration of the dissolved gas, (ii) the MB
shell composition (which controls the surface tension and
the resistance to permeation) and (iii) the solubility of the
encapsulated gas core in the medium.23 In 1950 Epstein and
Plesset introduced a model describing the rate of growth and/or
dissolution of ‘‘shell-less’’ or ‘‘uncoated’’ bubbles in aqueous
media and showed them to be critically dependent on the
diffusion of gas away from the bubble surface, Dw, the degree
of saturation of the solution, f (=C0/Cs), and the initial bubble
radius, r (Fig. 1). C0 is the concentration of dissolved gas and
Cs is the concentration at saturation.
24 More recently Borden
and Longo suggested a modified version of the Epstein–Plesset
model, as shown in eqn (1), that included the effect of the MB
coating as a barrier against gas diffusion, Rshell, and amodifier of
the surface tension, s.25
dr
dt
¼ Hr
Dw
þ Rshell
1þ 2s
Par
 f
1þ 4s
3Par
 !
(1)
where H is the Ostwald coefficient for the gas (the ratio of the gas
concentration in the aqueous phase to that in the gas phase in
contact with the aqueous phase).26,27
The Laplace pressure, DP, places the gas core under
increased pressure due to surface tension and curvature effects
and thus provides a strong driving force for MB dissolution.28
The inclusion of surfactants, in our case lipids, at the gas/liquid
interface significantly reduces the surface tension and, con-
sequently, the Laplace pressure.29,30 Such surfactants also
provide a resistive barrier, Rshell, to gas leaving the MB and
dissolving into the aqueous phase. Important shell properties
that affect the bubble stability are surface tension, surface
hardening, and resistance to gas transport.30–32 Borden and
Longo25 showed that MB stability is strongly dependent on the
lipid shell resistance and increases with the increasing acyl
chain length of the lipids.33–36 They also showed that increasing
the acyl chain length between DPPC (16) and DBPC (24)
increases the lipid rigidity (Wrinkling threshold) and con-
sequently the MB stability and circulation time. The use of higher
molecular weight, less soluble gases such as SF6 and perfluoro-
carbons (PFCs) also significantly enhances MB lifetime and
permits diagnostic and therapeutic applications.5,23,27,37 Several
groups have investigated the effect of different gases, or gas
mixtures, on MB stability. Sarker et al.27,38 developed a modified
EP model for gas diffusion from MBs filled with air and PFC gas
and showed that the dependence of shell permeability to gas type
predicts a 500 increase in the time taken for MB dissolution for
PFC compared to air filled bubbles. Kraft et al. used acoustical
methods, to investigate the effect of the gas composition on the
size and stability of shelled MBs. Using bubbles filled with
nitrogen and saturated with perfluorohexane, they reported that
the PFC gas increased the compressibility of the lipid monolayer
resulting in more flexible and stable MBs.39,40 Kabalnov et al.26,41
presented a detailed model and in vivo experimental studies on
the efficacy of different PFC gases (as osmotic agents) mixed with
oxygen or nitrogen on MB dissolution in the blood stream. They
showed an increase in the bubble lifetime with the increasing
molecular weight of the osmotic agent when mixed with oxygen.
Increasing the PFC molecular weight beyond C6F14 does not have
a positive effect. Finally, Schutt et al. encapsulated a mixture of
different PFCs in their gaseous state, to show that MBs containing
mixtures of C4F10 and C6F14 persist for 3 min, which was longer
than with either gas on its own.28,42
The combined effect of saturation of the surrounding
medium, f, and different MB shells, Rshell, was investigated by
Kwan and Borden in 2010.43 Sulphur hexafluoride, SF6, was
encapsulated in SDS or lipid shell MBs and used in a modified
perfusion chamber to observe the MB dissolution behaviour
in a SF6 or air-saturated medium. When suddenly placed in an
air-saturated medium, MBs initially grow (air influx) and then
decrease in size as a result of SF6 efflux. Lipid coated MBs
deviated from the model, as when placed in an air-saturated
environment, the initial growth regime was shorter and it was
followed by rapid non-uniform dissolution to the original
diameter, and then a steady dissolution with a constant wall
velocity and final stability at around 10 mm in diameter.
For the studies reported here, MF-MBs were produced with
an average diameter of 2 mm. The stability of the population
was examined in vitro, at 37 1C, and in vivo using mouse
models. The aim of the study was to optimize the in vivo
lifetime of the MF-MBs. Factors investigated include: shell
resistance, Rshell, through control over the lipid compositions,
and gas dissolution, (Dw, f, H), through control over the
molecular weight of the gas and saturation of the surrounding
medium. By optimising these factors we achieved a prolonged
lifetime of MBs in vivo. Our optimised MBs have lifetimes
of 414 minutes in vivo and also retain excellent ultrasound
contrast enhancement properties.
Fig. 1 Schematic representation of a lipid shelled MB illustrating the
factors that affect MB lifetime. The different terms are defined in the text.
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2 Materials and methods
2.1 Materials
The lipids used throughout this study were 1,2-dipalmitoyl-
sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-phosphoethanol-
amine-N-[methoxy(polyethylene-glycol)-2000] (DSPE-PEG2000), and
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy-
(polyethyleneglycol)-5000] (DPPE-PEG5000) which were purchased
from Avanti Polar Lipids (Alabaster, AL, USA) and used without
further purification. All lipids were received in the powder form,
and then dissolved in a 50/50 chloroform/methanol solution.
2.2 Microbubble preparation and characterisation
The lipid composition as specified for each MB formulation
was prepared as described previously.19,44 Briefly, the lipid
mixture was dried under a steady stream of nitrogen gas on
the vial walls. This dried film was then suspended in a solution
containing 4 mg mL1 NaCl and 1% glycerine (499%, Sigma-
Aldrich, St. Louis, MO, USA) to a final lipid concentration of
1 mg mL1 unless otherwise specified. This solution was
vortexed for 1 minute before being placed in an ultrasonic bath
for 1 hour. The lipid solutions were allowed to cool down in the
fridge for 5 minutes prior to use in the MF-MB maker.
Polymethylmethacrylate (PMMA) MF-chips, designed in
Leeds and produced by Epigem plc (Redcar, UK), were used
to prepare MBs according to our previously described protocols,
in which gas flow is focussed through a nozzle before being
rapidly expanded to create a microspray regime.19 Two gases
were investigated of different molecular weight: perfluoro-
propane gas (C3F8), Mw = 188 g mol
1; and perfluorobutane
(C4F10), Mw = 238 g mol
1. The gas pressure was controlled
using a Kukuke microprecision regulator (RS supplies, Leeds,
UK). The flow rate of the liquid phase, containing the lipid
products, was controlled using an Aladdin AL 2000 syringe
pump (World Precision Instruments, Stevenage, UK). The flow
rate was fixed for all MB preparations at 80 mL min1. In some
cases tetradecafluorohexane (C6F14, Sigma-Aldrich, St. Louis,
MO, USA) was used to saturate the lipid solution (10 mL).
A typical production run produced 1 mL of MBs. For each
MB population formed, a 10 mL sample (collected from the
middle of the homogenous MB solution) was diluted 10-fold to
facilitate counting and sizing of the bubbles. From this diluted
sample 30 mL was introduced into a 50 mm chamber on a glass
slide. The MBs were allowed to rise for B1 minute before
acquiring images. An inverted microscope (Nikon, Japan) was
used to image the MBs at 60 magnification. A CCD camera
(DS-Fil 5 Mega pixel, Nikon, Japan) was used to capture 40
images of each sample, from which the concentration and size
distribution were obtained using Image J freeware (http://
rsbweb.nih.gov/ij/) and statistically analysed using Origin Pro
(Version 8.5 or later).
2.3 In vitro lifetime
The MB lifetime was measured in vitro as described previously.45
Briefly, 500 mL of MB solution was introduced into 500 mL of cell
medium [RPMI from Invitrogen, Life Technologies, UK, with
10% (v/v) foetal calf serum (Sigma Aldrich, UK)] and incubated at
37 1C in a digital dryblock heater (Model D1100, Labnet Inter-
national, USA). The vial containing the sample was left open
exposed to air and 10 mL samples were collected every 15 min for
sizing and counting.
2.4 In vivo lifetime
For in vivo measurements 50 to 100 mL of the MB solution
(in PBS) was injected via a syringe attached to a tail vein
catheter. The injection of the MB bolus was controlled by a
syringe driver at a rate of 0.6 mL min1. A typical bolus
contained B108 MBs in 100 mL.
All animal work was performed under licence and in accordance
with the UK Animals (Scientific Procedures) Act 1986 following
local ethical review and procedures. Eighteen athymic CD1-nu/nu
malemice (6–8 weeks old) were maintained in individual ventilated
cages under specific pathogen-free conditions with free access
to diet and water.
The mouse aorta was identified and imaged by pulsed wave
(PW) Doppler imaging using a Vevo770 (FUJIFILM VisualSonics,
Inc.) using the 40 MHz transducer. For post-processing analysis,
a region of interest (ROI) was drawn within the aorta such that
the ROI was maintained within the aorta for the whole video
loop, ensuring that with respiration motion, the ROI was not
sampling tissue outside the aorta, as indicated by the blue circle
in Fig. 2A. Fig. 2B shows a snapshot of the accumulation of MBs
in the aorta post injection.
2.5 Langmuir trough
A Langmuir trough (KSV Nima) was used to measure the
differences in monolayer compressability and elasticity. The
trough was equipped with twomovable PTFE barriers to compress
the monolayer symmetrically. A Wilhelmy plate tensiometer
(paper method) was used to measure the surface pressure of the
monolayer. This experiment was performed for the same lipid
monolayer composition found to form the most stable MBs.
20 mL of a 1 mg mL1 solution of (DPPC + 5% DSPE-PEG2000),
in chloroform, was spread on the surface of a subphase of water
Fig. 2 In vivo imaging of mouse aorta with high frequency ultrasound.
(A) A region of interest (ROI) within the aorta was selected for post-processing
analysis (blue region) to determine the contrast intensity within the aorta over
time. (B) Example image showing the aorta post injection filled with MBs.
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in the presence and absence of C6F14. Pressure–area isotherms
were made with the compression rate of the barriers set to
5 mm min1 and the surface pressure was not allowed to rise
beyond 30 mN m1; this ensured the reversibility of the
isotherms and allowed us to observe multiple compression/
expansion cycles, which is important for the determination
of whether any material is lost from the monolayer during
compression.
3 Results
3.1 Microbubble production and characterisation
MBs were prepared in the spray regime of a specially designed
MF-chip19 shown schematically in Fig. 3A. The image (inset) in
Fig. 3B shows a typicalMB population, with an averageMBdiameter
of 1.7  1.1 mm and concentrations of B2  109 MB mL1.
No bubbles were produced with a diameter 47 mm.
3.2 MB lifetime
In vitro MB lifetime was initially determined by measuring the
MB concentration, using optical microscopy, every 30 min in a
closed vial at room temperature and atmospheric pressure. MB
concentration versus time (in vitro results) for MBs prepared
with shells of DPPC (or DSPC) with 10% DSPE-PEG2000 encap-
sulating C3F8 gas was tested (see S1, ESI†). The data showed
that the MBs were relatively long lived in both cases, i.e. for
both lipid types, with no significant difference in their stability
over a period of B3 h following production. In contrast, the
in vivo lifetime in the mouse aorta, as determined from time–
intensity curves (TICs), showed that both MBs decayed within
2 minutes in vivo. A slightly higher acoustic intensity signal was
observed for the DPPC MBs compared to the DSPC ones, which
is consistent with previous observations for such MBs.46 These
initial results showed that the in vitro study of MBs, at room
temperature and atmospheric pressure, is not a good indicator
of the in vivo behaviour and that physiological conditions
(increased temperature, pressure and potential for gas exchange
around the MBs) are likely to significantly affect the MB stability.
Thus, in order to better test our MBs under more realistic
conditions the in vitro experiment was modified to use a cell
medium (RPMI with 10% (v/v) foetal calf serum) incubated at
37 1C and the sample was left in an open tube exposed to air for
gaseous exchange. Based on the in vivo data (S1, ESI†), and that
DPPC MBs have a more homogenous lipid distribution on the
bubble shell,47 the slightly shorter DPPC (16 : 0) lipid was chosen
for subsequent MB studies over the DSPC (18 :0). A series of factors
were investigated to detect their effect onMB stability, firstly in vitro
and then in vivo. These included: (i) the degree of pegylation in the
MB shell, which affects the potential for phase separation;45,48
(ii) the gas core, by switching to a heavier gas (C4F10) to reduce
solubility and diffusivity in the surrounding medium; and finally
(iii) factors related to the surrounding solution, such as super
saturating the lipid solution with C3F8 gas prior to bubble produc-
tion, and also increasing the concentration of NaCl in the lipid
solution to over 0.1 M to prevent bubble fusion.49
Of the factors identified above only two showed a significant
effect on MB stability. Summary data has been taken from a
larger data set of the variables investigated, which is detailed in
the ESI† (S2). The first significant effect was that on changing
from the C3F8 core to the higher molecular weight C4F10 gas,
the MB population displayed a doubling in lifetime from the
order of one to two hours (at 37 1C) Fig. 4A. This effect is well
understood and is due to the reduced solubility of the higher
Fig. 3 Bubble production and characterisation. (A) A schematic of the
microfluidic chip design emphasizing the 3D expansion region for the
production of MBs in the spray regime. (B) Graph displaying the size
distribution for one of the bubble populations. The inset shows a bright
field image representing the produced MBs (sample is 10-fold diluted).
Fig. 4 (A) MB concentration versus time for DPPC + 5% PEG DSPE MBs
with C3F8 and C4F10 gas cores. (B) The effect of adding liquid C6F14 to the
MB bolus, in increasing amounts from 0 to 15 mL mL1, on MB lifetime.
(C) Calculated lifetime expected for the MB distribution profile shown in
Fig. 3 for 3 cases, (i) with a C3F8 core, (ii) with a C4F10 core and (iii) C4F10 + C6F14
(open circles). The parameters for calculations were taken from Sarkar27 and
given in detail in the ESI† (S4). All data was taken at 37 1C in cell media and at
atmospheric pressure.
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Mw gas in solution (the Ostwald coefficient reduces from
5.2  104 for C3F8 to 2.0  104 for C4F10), a slightly reduced
diffusion rate in water (from 7.45 1010 for C3F8 to 6.9 1010
for C4F10) and an increase in the resistance of the shell
to the increased Mw gas. These effects have been modelled
in S3 in the ESI†, following the work of Sarkar et al.27,38 for
MBs with different cores and assuming the surface tension of
the shelled MBs to be 25 mN m1.
Decreasing the PEG concentration from 10% to 5% led to a
modest increase in the average lifetime (S4, ESI†). However, in
spite of this significant improvement in the in vitro lifetime,
at body temperature, these formulations showed negligible
improvement in the in vivo MB lifetime, as indicated by the
TIC curves (S4, ESI†).
To control the saturation, f, or solubility of the gas in the
solution, H, the medium containing the MBs was saturated with
C6F14, which is a liquid at room temperature. The solubility of
C6F14 in water, at 25 1C, is 2.7 104 mol L1, which is equivalent
to B0.05 mL for 1 mL of the lipid solution.11,50 The volume of
C6F14 per mL of MB was varied between 0 and 15 mL mL
1 in
the lipid solution (DPPC + 5% DSPE-PEG2000) to determine the
optimum concentration at which the MBs have the longest life-
time. Fig. 4B shows the fraction of bubbles remaining in the
medium at 37 1C, as a function of time for different volumes of
C6F14 added to a 1 mLMB bolus. The data shows that MB lifetime
was significantly increased upon the addition of C6F14 for con-
centrationsZ6 mL mL1, with the 15 mL mL1 sample producing
the most stable MB population. However, the addition of such
volumes of C6F14 adversely affected the MB production leading to
a 10-fold reduction in the concentration of MBs produced. Thus
the addition of 10 mL of C6F14 was selected as being the optimal
amount. At this concentration MBs were still produced at a high
concentration ofB1  109 MB mL1 whilst also increasing MBs
stability. The MB decay rate was reduced to only 0.07% over the
2 h period.
Fig. 4C shows the calculated MB population profile expected
based on the calculation of a typical MB distribution, given
in Fig. 3B, and that the MBs decay in accordance with the
modified Epstein–Plesset model proposed by Borden25 and
Sarkar.27 In these models the surface tension was assumed to
be 25 mN m1 and the saturation, f, was taken as unity, and all
other parameters are given in the ESI.† We note that in this
model MBs of a diameter o0.5 mm were considered to not be
observable optically and so bubbles were removed from the MB
population when their size decreased below 0.5 mm. Essentially
we see the expected trend that C4F10 4 C3F8, however we note
that the model predicts longer lifetimes than were experi-
mentally observed, probably indicating that the MB surface
tension, shell resistance and/or the degree of saturation are not
accurately modelled in our system.
Fig. 5A shows the in vivo TIC for four different MB variants,
comparing both the effect of the presence of C6F14 in the bolus
and the concentration of the lipid. Comparison of the area
under the curves for the cases with and without C6F14 clearly
indicates that the presence of C6F14 significantly enhances
MB persistence in the bloodstream. Furthermore, by doubling
the lipid concentration, from 1 mg mL1 to 2 mg mL1, during
the production of the MBs, the concentration of the MBs was
doubled from 1  109 to 2  109 MB mL1, and the lifetime was
modestly enhanced, leading to a larger area beneath the TIC
curves. Fig. 5B shows the TIC curves for our best in vivo MB in
comparison to those obtained using commercially available
MBs (Micromarker (MM), Definity).
For each MB population the intensity versus time curves
were collected from 5 mice, and from each curve 6 different
parameters were extracted, as shown in Fig. 6A. These can
facilitate the comparison of the different MBs and aid the
determination of the one with the best properties for in vivo
imaging. These parameters are presented with the codes as
follows: (1) rate of decay. This can be calculated from the slope
of the curve after the peak point. The smaller the decay rate the
longer the MB lifetime. (2) Peak enhancement, which is the
point at the highest contrast intensity. This mainly depends on
the MB shell properties and concentration. (3) Area under the
curve, which is proportional to both the MB concentration and
persistence time. A greater area indicates better quality and
stability of MBs. (4) Time to peak, which is the time to reach the
maximum intensity at the ROI. It is better if this is short. (5)
Peak enhancement duration, which is the time at which there
was the highest contrast intensity after injection. (6) Time to
Fig. 5 Ultrasound time intensity curves in mice aorta. (A) shows the effect of increasing the final lipid concentration, and saturating the lipid solution with
C6F14 on MB lifetime for MBs made with DPPC + 5% PEG2000 and encapsulating C4F10 gas. (B) compares TIC curves for our improved in-house MBs and
commercial MBs.
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half peak contrast. The longer this parameter is, the more
prolonged the lifetime of the MBs is at the ROI.
Fig. 6B shows the data analysis for the TIC curves comparing
the six parameters between our in-house MF-MBs and the
commercially available MBs. The data suggests that the MF-MBs
produced in-house display an improved peak enhancement and
area under the curve, and a significantly longer time to half peak.
In order to understand the role of C6F14 in enhancing MB
lifetime, a Langmuir trough was used to plot the relationship of
the surface pressure, P (mN m1), versus the average molecular
area, for a 1 mg mL1 (DPPC + 5% PEG2000) solution spread at
the air/water interface in the presence and absence of C6F14 in
the sub-phase. Fig. 7 shows the compression isotherms of the
monolayer. All conditions are fixed for both cases with the only
difference being the sub-phase; either just with MilliQ water or
MilliQ water plus C6F14 at the same concentration used during
MB production (10 mL mL1).
The mean molecular area was found to increase from
0.5 nm2 to 0.63 nm2 upon the inclusion of C6F14 in the sub-
phase, which indicates the incorporation of the C6F14 molecules
within the lipid layer. The fractional component of C6F14 in theMB
shell was calculated to be 0.4, whichmeans an estimation of 2 PFC
molecules for every 5 lipid molecules. As a consequence of
incorporating C6F14 (surface tension 11 mNm
1 51) at this propor-
tion in the lipid layer, the surface tension of the monolayer is
reduced from 25 mN m127,38 to 19 mN m1. Consequently, this
leads to a reduction in the Laplace pressure from 50  103 N m1
in the absence of C6F14, to 38  103 N m1 in the presence of
C6F14, which leads to an improved estimate in the MB lifetime.
The hollow circles in Fig. 4C indicate the predicted enhancement
in MB lifetime due to the reduction in surface tension. This is
shown more clearly in S3 (ESI†).
The isothermal compressibility, C, and the compression
modulus (elasticity), K, of the lipid modified interface are
calculated from the extrapolated lines shown on the isotherm
(Fig. 7). These calculations showed that the existence of PFC in
the surrounding solution increased the compressibility (C)
from 1.0  102 to 1.2  102 m mN1, which corresponds to
a decrease in the elasticity (K) from 97 mNm1 to 88 mNm1 in
the presence of PFC molecules. These results are in good
agreement with the previously published work by Krafft39 on
the effect of saturating the surrounding air with different PFC
gases on the compressibility and elasticity of lipid monolayers.
4 Discussion and conclusion
MB lifetime stability has been investigated by changing different
factors that are known to have an effect on MB lifetime. The MB
architectures have a shell comprising a DPPC/DSPE-PEG2000
Fig. 6 In vivo TIC analysis. (A) shows an example time–intensity curve
(TIC) for MB flow in a mouse aorta and defines six key parameters for
defining MB lifetime: (1) is the decay rate calculated from the slope of the
curve after the peak intensity, the slower the decay rate the greater the MB
stability; (2) is the peak enhancement, which is the maximum intensity
signal, and is due to the MB shell properties as well as the gas used; (3) is
the area under the curve, which indicates the signal from the total MB
population present and therefore the concentration of MBs; (4) is the time
to peak, which is the time to reach the peak signal intensity, it should be
short enough to enable imaging within a realistic time-frame; (5) is the
peak enhancement duration, which is the length of time the MB signal
persists, this needs to be of sufficient duration to allow a useful imaging
session following MB injection; (6) is the time to half peak, which is the
time it takes the signal to reduce to half the peak intensity, which is a
further measure of the duration of the signal. (B) The six parameters for our
in-house MBs and two commercial MB formulations. In-house MBs
showed (1) slower decay rate, (2) improved peak enhancement signal
and (5) duration, (3) larger area under the curve, (4) shorter time after
injection to reach the maximum intensity, and (6) significantly longer time
to half peak, indicating better in vivo stability, better contrast enhancement
and longer imaging time.
Fig. 7 Langmuir isotherms of DPPC + 5% DSPE-PEG2000 monolayers, on
water sub-phase (black) and water with 10 mL mL1 C6F14 added to the
sub-phase (red). Dashed lines show the extrapolated average molecular
area for the DPPC/DSPE-PEG2000 phase.
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binary system, the components of which are completely miscible
below 15% PEG2000 concentrations forming a single condensed
phase with low permeability.52 We have previously shown that
reducing the PEG2000 concentration from 10 to 5% helped
increase the MB lifetime.45 MB lifetime was also improved by
changing the encapsulated gas from C3F8 to one with a larger
molecular weight, i.e. C4F10. This decreases the coefficient of
diffusivity from 7.45 1010 to 6.9  1010 m2 s1.27 Combining
the changes outlined above has resulted in a considerable
improvement in the in vitro lifetime of the MBs, as discussed
in the Results section above.
Recently, C6F14 has been encapsulated together with Dox
or gold nano-rods in nanoparticles and locally activated at the
site of a tumour to form MBs, and C6F14 had been shown to
enhance the acoustic imaging, cavitation and therapeutic
delivery effects.53,54 In this work, saturating the medium sur-
rounding the MBs with liquid C6F14 and using C4F10 in the gas
core are considered key to the improvements in MB lifetime.
The presence of C6F14 in the surrounding medium increased
the stability and lifetime of the MBs in vitro and showed an
improvement of up to 14 min in vivo (Fig. 5). We believe this
improvement in stability arises for two reasons (Fig. 8); firstly,
the addition of C6F14 effectively results in the saturation of the
surrounding medium, reducing the ability for C4F10 to partition
into the aqueous phase. Secondly, the incorporation of C6F14
molecules into the lipid shell of the MB, as concluded from
Fig. 7, leads to a 25% reduction in the surface tension of the
membrane, and hence also a reduction in the Laplace driving
force for dissolution. This also modifies the mechanical properties
of the shell, where a 17% increase in the compressibility is
observed accompanied by a 10% decrease in the shell elasticity.
The effect of saturating the gas medium with PFC gases on the
lipid monolayers has been studied by Gerber et al.,55,56 who
saturated the atmosphere above the Langmuir monolayer of DPPC
with vapours of C6F14. They reported that saturating the gaseous
medium with PFC gas has a fluidizing effect on the DPPC
monolayer adsorption at the gas/water interface, as it prevents
the liquid condensed phase formation and hinders lipid crystal-
lisation. Krafft et al.39 also demonstrated that DMPC lipid shell
MBs showed a 20% increase in compressibility of the membrane
and a 26% decrease in the surface tension upon saturating the air
with C6F14 in the gas medium. Krafft and Fainerman et al.
57,58
theoretically modelled and practically showed that in case of DPPC
monolayers, saturating the gas phase with C6F14 led to C6F14
molecules being adsorbed at the lipid surface, causing a reduction
in the energy of attraction between the DPPC molecules, which
leads to a fluidization of the monolayer. From the data shown here
it appears that the surface tension alone is not a significant
enough change to account for the increased MB stability and thus
we also believe that the inclusion of the C6F14 molecules into the
lipid chain must also increase the shell resistance.
In vivo MB lifetime improved from 2 min to 14 min through
a combination of changes to the lipid shell, the gas core and the
addition of C6F14 to the medium. Furthermore, comparing
in-house MF-MBs and commercial MBs (Fig. 5) showed that
the sat-C4F10 MBs provided enhanced lifetime and contrast
properties compared to their commercial counterparts.
In conclusion, control of MB properties including decay
rate, intensity and enhancement duration, was achieved by
changing the phospholipid shell composition, the encapsu-
lated gas and, most significantly, the degree of saturation of
the surrounding medium with C6F14. Our data suggests the
C6F14 molecules are incorporated in the lipid shell reducing
the surface tension and also increasing the mechanical com-
pressibility and collapse pressure. MBs for drug delivery appli-
cations are likely to require longer lifetimes to allow for
accumulation at the ROI for optimal dose delivery and will
thus benefit greatly from such improvements.
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